inHEART, a medical device company delivering AI-driven digital twin of the heart, has raised $11M to drive commercial growth of its therapeutic software solution for cardiac ablation procedures and advance the development of its predictive cardiac models for heart failure, sudden cardiac death, and cardio-embolic stroke.

The financing was led by Vesalius Biocapital IV and co-led by Elaia Partners with participation from NACO, Sagana, Sofia Angel Ventures, CWR Funds, and Webit Investment Network. In addition, inHEART received funds from a successful crowdequity campaign on Tudigo and from the UK impact fund Astorg Foundation.

The funding will also support commercial expansion of inHEART’s digital twin of the heart in the US, EU, Asia Pacific, and Middle East markets. 

“We welcome this strong international group of investors to our latest round of financing,” said Todor Jeliaskov, Chairman and CEO of inHEART. “This new round allows us to go further in addressing the needs of cardiac patients from early screening and disease detection through advanced therapeutic support. It’s exciting for us to be at the forefront of transforming the healthcare industry with the power of AI technology by improving the efficiency of care, quality of decision-making, and effectiveness and safety of medical interventions.” 

Optimizing cardiac care

inHEART’s current therapeutic solution addresses the challenges of conventional cardiac ablations. The inHEART solution creates highly detailed, interactive 3D heart models with proprietary AI-driven cardiac CT or MR image segmentation. These 3D models of the heart allow physicians to optimize treatment strategies based on each patient’s unique cardiac anatomy and to support pre-procedural planning for faster ablation procedures and improved clinical outcomes.

AI-driven predictive models

Financing from this round will also support the development of new product verticals for AI-driven predictive software models for sudden cardiac death and cardio-embolic stroke, as well as a new therapeutic software solution to help physicians treat heart failure patients. Currently, inHEART is commercially available in the US and EU through a direct sales force model, with plans to establish a global distribution network in the coming months to further accelerate growth.

The post inHEART, a startup that’s building digital twin of the heart, raises $11 mn appeared first on CIO Dimension.

MedTech company Siemens Healthineers and the Indian Institute of Science (IISc) inaugurated the Siemens Healthineers-Computational Data Sciences (CDS) Collaborative Laboratory for AI in Precision Medicine at IISc Bangalore. The CDS collaborative laboratory will develop open-source AI-based tools to precisely automate the segmentation of pathological findings in neuroimaging data, with a focus on accurately diagnosing neurological diseases and analyzing their clinical impact at a population level.

The laboratory has been established with the support of Siemens Healthineers Corporate Social Responsibility initiative, which also includes six M.Tech fellowships for women, aiming to enhance female representation in artificial intelligence. Dr. Vaanathi Sundaresan of IISc’s Department of CDS will lead the program. The focus of this collaborative laboratory will be to work closely with neurologists, radiologists and Siemens Healthineers and integrate the developed computational models into their regular clinical workflows.

Speaking on the partnership, Peter Schardt, Chief Technology Officer, Siemens Healthineers, who inaugurated the facility, said, “The collaboration with IISc solidifies our commitment to advancing precision medicine through AI using state-of-the-art, data-driven deep-learning techniques. Leveraging IISc’s academic excellence and our strong core in medical imaging, smart solutions developed through this collaboration will help us ultimately save lives through precise diagnoses and evidence-based treatments”.

Prof Govindan Rangarajan, Director, Indian Institute of Science, said, “This lab marks a crucial step forward in unlocking the potential of AI for precision medicine. Together, we are accelerating the future of healthcare for everyone. This collaboration is a powerful example of how industry and academia can come together to tackle complex challenges.”

The company stated that the partnership between Siemens Healthineers and IISc is a milestone in artificial intelligence research in India, aiming to combat the world’s most threatening neurovascular diseases and pioneer breakthroughs in healthcare.

Dileep Mangsuli, Executive Director, Siemens Healthineers, said “… Along with IISc, we aim to reshape the landscape of neuroscientific progress through the capabilities of artificial intelligence, translating laboratory insights into intelligent solutions. We want to empower the broader clinical research community and be changemakers in the fight against world’s most life-threatening diseases.”

Prof Navakanta Bhat, Dean, Division of Interdisciplinary Sciences, IISc, added, “We are very excited about this partnership that offers healthcare innovation possibilities by leveraging deep expertise of IISc faculty and students in the area of artificial intelligence along with the medical imaging expertise of Siemens Healthineers, an industry leader in this field. The focus on neuroimaging is also timely, given the growing incidence of age-related disorders of the brain. We hope that this partnership will develop new tools for early diagnosis of a variety of neurological diseases.”

The post Siemens Healthineers, IISc launch laboratory for AI in precision medicine  appeared first on CIO Dimension.